NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
14 September 2024
| Name: | NEUROTECH INTERNATIONAL LIMITED (NTI) |
| ISIN: | AU000000NTI9 |
| Date of Listing: | 04 November 2016 |
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 610 205 402ABN: 73 610 205 402
Registration Date: 15 January 2016
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
Automic Registry Pty Ltd
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Neurotech International Limited will be lifted immediately following the release by NTI of an announcement regarding a capital raise. | 28/10/2022 |
The company releases an Investor Presentation. | 28/10/2022 |
The company releases a notice of proposed issue of securities. | 28/10/2022 |
Single tranche share Placement conducted following further strong clinical trial results at 20 weeks for NTI164 in children with Autism Spectrum Disorder. Binding commitments for a $9.0 million Placement with support from existing and new institutional, professional and sophisticated Australian and overseas investors. Capital raised fully funds multiple Phase I/II clinical trials in PANDAS/PANS and cerebral palsy, a large Phase II/III trial in ASD and various US FDA initiatives. | 28/10/2022 |
The securities of Neurotech International Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NTI, pending the release of an announcement regarding a capital raise. | 27/10/2022 |
The suspension of trading in the securities of Neurotech International Limited will be lifted immediately following the release by NTI of an announcement regarding the results of its Phase I/II clinical study of the NTI164 strain in paediatric Autism Spectrum Disorder. | 08/07/2022 |
93% of patients showed symptom improvement relating to the severity of illness after 28 days of daily treatment with NTI164. 64% of patients had a global improvement of "much improved'". 29% of patients had a global improvement of "minimally improved". 7% of patients had "no change". Two patients recorded a Marked Therapeutic Index Score of 2 = vast improvement meaning: complete or near remission of all symptoms. Ten patients recorded a Moderate Therapeutic Index Score of 5 & 6 = representing "Decided improvement" "“ Partial remission of symptoms. The average rating for the severity of illness at baseline was 4.4. This was reduced to 3.6 after 28 days of NTI164 treatment. NTI164 was well-tolerated "“ No serious adverse events were recorded across all doses (5, 10, 15 and 20 mg/kg). No changes were noted in blood analysis or liver function tests. The study has been granted HREC approval to continue for a further 54 weeks due to the positive therapeutic effects of NTI164 combined with feedback from parents and clinicians and their recent request for no "washout" period. Safety and efficacy assessments will continue. ï‚· The Company is in discussions with the US FDA regarding a pre-IND application scheduled for 2022. ï‚· Existing prescribed medications for the treatment of symptoms associated with ASD have untoward side effects including weight gain, sedation and hormonal imbalance. Given that NTI164 was welltolerated without weight gain or sedation, NTI164 shows promise compared to these treatments . Recently completed and published paediatric ASD studies utilising CBD and/or THC do not show any statistical efficacy and had minimal effects after three plus months and (with a THC component) had "˜sedation' as a significant side effect2,3. NTI164 measures favourably when compared to these treatments. The results open up opportunities for a potential treatment pathways outside of ASD including a wide range of neurological disorders such as Attention Deficit Hyperactivity Disorder ("ADHD"), Multiple Sclerosis, Motor Neuron Disease, Rett's Syndrome, Concussion and Cerebral Palsy. Conference Call with CEO, Dr Alexandra Andrews to be held at 11am WST today "“ details to follow. | 08/07/2022 |
The company wishes that its voluntary suspension remain in place until such time as the announcement regarding the results of its Phase I/II clinical study of the NTI164 strain in paediatric Autism Spectrum Disorder is released to the market, or until the commmencement of trade on 8 July 2022. | 07/07/2022 |
The securities of Neurotech International Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NTI, pending the release of an announcement regarding the results of its Phase I/II clinical study of the NTI164 strain in paediatric Autism Spectrum Disorder. | 06/07/2022 |
The suspension of trading in the securities of Neurotech International Limited will be lifted immediately, following the release by NTI of an announcement regarding further results of the in-vitro cell studies of its cannabis strains. | 30/11/2020 |
DOLCE/NTI leads indicate significant increased potency in repairing brain cells when compared to CBD alone. These results have been achieved using 1/5th the dose of CBD alone. DOLCE/NTI leads found to exhibit novel modes of action critical in the treatment and management of Alzheimer's, Huntington's Disease, Multiple Sclerosis and other neurological disorders. DOLCE/NTI leads contains minimal THC (<0.3%) which may result in less onerous regulatory pathway towards commercialisation. Final In-vitro results expected next month. Conference call to be held at 11am AWST today. | 30/11/2020 |
The securities of Neurotech International Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NTI, pending the release of an announcement regarding further results of the in-vitro cell studies of its cannabis strains. | 27/11/2020 |
The suspension of trading in the securities of Neurotech International Limited will be lifted immediately following receipt of a response to ASX's Price and Volume Query. | 01/05/2020 |
The company issues a Response to ASX Price and Volume Query. | 01/05/2020 |
The company lodges its Quarterly Report and Appendix 4C. | 29/04/2020 |
The company requests the voluntary suspension remain in place until such time as it makes an announcement to the market in relation to the ASX price query or the commencement of trade on Monday 4th May 2020. | 28/04/2020 |
The company requests the voluntary suspension remain in place until such time as it makes an announcement to the market in relation to the ASX price query or the commencement of trade on Tuesday 28th April 2020. | 20/04/2020 |
The securities of Neurotech International Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NTI, pending the release of an announcement regarding a response to a price query. | 14/04/2020 |
The suspension of trading in the securities of Neurotech International Limited will be lifted immediately, following the release by the Company of an announcement regarding a capital raising. | 16/10/2017 |
The company has successfully completed a well oversubscribed A$4 million placement of new shares to drive the company's ongoing commercialisation of the Mente Autism device. | 16/10/2017 |
The securities of Neurotech International Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement. | 12/10/2017 |
listed entity carried for record purposes only | 04/11/2016 |
The suspension of trading in the securities of Neurotech International Limited will be lifted immediately following the release by NTI of an announcement regarding a capital raise. | 28/10/2022 |
The company releases an Investor Presentation. | 28/10/2022 |
The company releases a notice of proposed issue of securities. | 28/10/2022 |
Single tranche share Placement conducted following further strong clinical trial results at 20 weeks for NTI164 in children with Autism Spectrum Disorder. Binding commitments for a $9.0 million Placement with support from existing and new institutional, professional and sophisticated Australian and overseas investors. Capital raised fully funds multiple Phase I/II clinical trials in PANDAS/PANS and cerebral palsy, a large Phase II/III trial in ASD and various US FDA initiatives. | 28/10/2022 |
The securities of Neurotech International Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NTI, pending the release of an announcement regarding a capital raise. | 27/10/2022 |
The suspension of trading in the securities of Neurotech International Limited will be lifted immediately following the release by NTI of an announcement regarding the results of its Phase I/II clinical study of the NTI164 strain in paediatric Autism Spectrum Disorder. | 08/07/2022 |
93% of patients showed symptom improvement relating to the severity of illness after 28 days of daily treatment with NTI164. 64% of patients had a global improvement of "much improved'". 29% of patients had a global improvement of "minimally improved". 7% of patients had "no change". Two patients recorded a Marked Therapeutic Index Score of 2 = vast improvement meaning: complete or near remission of all symptoms. Ten patients recorded a Moderate Therapeutic Index Score of 5 & 6 = representing "Decided improvement" "“ Partial remission of symptoms. The average rating for the severity of illness at baseline was 4.4. This was reduced to 3.6 after 28 days of NTI164 treatment. NTI164 was well-tolerated "“ No serious adverse events were recorded across all doses (5, 10, 15 and 20 mg/kg). No changes were noted in blood analysis or liver function tests. The study has been granted HREC approval to continue for a further 54 weeks due to the positive therapeutic effects of NTI164 combined with feedback from parents and clinicians and their recent request for no "washout" period. Safety and efficacy assessments will continue. ï‚· The Company is in discussions with the US FDA regarding a pre-IND application scheduled for 2022. ï‚· Existing prescribed medications for the treatment of symptoms associated with ASD have untoward side effects including weight gain, sedation and hormonal imbalance. Given that NTI164 was welltolerated without weight gain or sedation, NTI164 shows promise compared to these treatments . Recently completed and published paediatric ASD studies utilising CBD and/or THC do not show any statistical efficacy and had minimal effects after three plus months and (with a THC component) had "˜sedation' as a significant side effect2,3. NTI164 measures favourably when compared to these treatments. The results open up opportunities for a potential treatment pathways outside of ASD including a wide range of neurological disorders such as Attention Deficit Hyperactivity Disorder ("ADHD"), Multiple Sclerosis, Motor Neuron Disease, Rett's Syndrome, Concussion and Cerebral Palsy. Conference Call with CEO, Dr Alexandra Andrews to be held at 11am WST today "“ details to follow. | 08/07/2022 |
The company wishes that its voluntary suspension remain in place until such time as the announcement regarding the results of its Phase I/II clinical study of the NTI164 strain in paediatric Autism Spectrum Disorder is released to the market, or until the commmencement of trade on 8 July 2022. | 07/07/2022 |
The securities of Neurotech International Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NTI, pending the release of an announcement regarding the results of its Phase I/II clinical study of the NTI164 strain in paediatric Autism Spectrum Disorder. | 06/07/2022 |
The suspension of trading in the securities of Neurotech International Limited will be lifted immediately, following the release by NTI of an announcement regarding further results of the in-vitro cell studies of its cannabis strains. | 30/11/2020 |
DOLCE/NTI leads indicate significant increased potency in repairing brain cells when compared to CBD alone. These results have been achieved using 1/5th the dose of CBD alone. DOLCE/NTI leads found to exhibit novel modes of action critical in the treatment and management of Alzheimer's, Huntington's Disease, Multiple Sclerosis and other neurological disorders. DOLCE/NTI leads contains minimal THC (<0.3%) which may result in less onerous regulatory pathway towards commercialisation. Final In-vitro results expected next month. Conference call to be held at 11am AWST today. | 30/11/2020 |
The securities of Neurotech International Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NTI, pending the release of an announcement regarding further results of the in-vitro cell studies of its cannabis strains. | 27/11/2020 |
The suspension of trading in the securities of Neurotech International Limited will be lifted immediately following receipt of a response to ASX's Price and Volume Query. | 01/05/2020 |
The company issues a Response to ASX Price and Volume Query. | 01/05/2020 |
The company lodges its Quarterly Report and Appendix 4C. | 29/04/2020 |
The company requests the voluntary suspension remain in place until such time as it makes an announcement to the market in relation to the ASX price query or the commencement of trade on Monday 4th May 2020. | 28/04/2020 |
The company requests the voluntary suspension remain in place until such time as it makes an announcement to the market in relation to the ASX price query or the commencement of trade on Tuesday 28th April 2020. | 20/04/2020 |
The securities of Neurotech International Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NTI, pending the release of an announcement regarding a response to a price query. | 14/04/2020 |
The suspension of trading in the securities of Neurotech International Limited will be lifted immediately, following the release by the Company of an announcement regarding a capital raising. | 16/10/2017 |
The company has successfully completed a well oversubscribed A$4 million placement of new shares to drive the company's ongoing commercialisation of the Mente Autism device. | 16/10/2017 |
The securities of Neurotech International Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement. | 12/10/2017 |
listed entity carried for record purposes only | 04/11/2016 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 29/01/2024 | Thomas Duthy | 340,000 | $0.091 | $30,820 |
| 02/08/2022 | Gerald Quigley | 277,777 | $0.090 | $25,000 |
| 14/07/2021 | Krista Bates | 180,000 | $0.056 | $10,044 |
| 14/07/2021 | Allan Cripps | 180,000 | $0.056 | $10,018 |
| 22/06/2021 | Brian Leedman | 933,589 | $0.054 | $49,962 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Mark Davies | Non Exec Chairman, Independent Director | 16/04/2019 |
| Alexandra Andrews | COO | 08/03/2022 |
| Richard Small | CFO, COO | 04/11/2016 |
| Max Johnston | Non Exec Director | 19/04/2024 |
| Gerald Quigley | Non Exec Director | 07/07/2022 |
| Thomas Duthy | Executive Director | 01/09/2022 |
| Alessandra Gauvin | Company Secretary | |
| Erlyn Dale | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Winton Willesee | Independent Director | 16/04/2019 | 19/04/2024 |
| Allan Cripps | Non Exec Director | 19/05/2021 | 21/12/2022 |
| Brian Leedman | Non Exec Chairman | 19/10/2020 | 16/08/2022 |
| Krista Bates | Non Exec Director | 05/04/2021 | 16/08/2022 |
| Peter Griffiths | Executive | 04/11/2016 | 21/10/2020 |
| David Cantor | Non Exec Director | 04/07/2018 | 19/10/2020 |
| Peter O'Connor | Chairman | 04/11/2016 | 16/04/2019 |
| Neale Fong | Non Exec Director | 03/10/2018 | 16/04/2019 |
| Simon Trevisan | Non Exec Director | 04/11/2016 | 16/04/2019 |
| Cheryl Tan | Non Exec Director | 04/11/2016 | 02/12/2018 |
| Wolfgang Storf | Managing Director, CEO | 04/11/2016 | 26/11/2018 |
| Adrian Trevisan | Non Exec Director | 15/01/2016 | 28/06/2018 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
